This PDF file includes:

• Supplementary Results
• Supplementary Materials and Methods
• Fig. S1. General procedure for the preparation of KDS compounds.
• Fig. S2. Structure-activity relationship of the synthesized compounds.
• Fig. S3. The KINOMEscan screening results with 1000 nM KDS2010 for off-target selectivity.
• Fig. S4. Mode of KDS2010 binding with MAO-B.
• Fig. S5. Three-day and 2-day interactions of selegiline, KDS2010, and KDS0014 inside MAO-B.
• Fig. S6. Acute treatment of KDS2010 (3 days) restored memory impairment in APP/PS1 mice.
• Fig. S7. Passive avoidance test for learning and memory in APP/PS1 mice with 2-week KDS2010 treatment.
• Fig. S8. KDS2010 significantly recovers spatial learning and memory in Morris water maze.
• Fig. S9. Model diagrams of long-term treatment of AD with either irreversible or reversible MAO-B inhibitors.
• Fig. S10. Data distribution of bar graphs.
• Table S1. Inhibitory effects of the synthesized compounds against hMAO enzymes.
• Table S2. In vitro and in vivo ADME/Tox profile of KDS2010.
• Table S3. In vivo pharmacokinetic parameters of KDS2010.
• Table S4. KDS2010 interactions with 87 primary molecular targets including GPCRs, kinases, non-kinase enzymes, nuclear receptors, transporters, and various ion channels.
• Table S5. KDS2010 interactions with 97 kinase including TK, TKL, STE, CK1, AGC, CAMK, CMGC, ATYPICAL, LIPID, and Mutant form.
• Table S6. Detailed information for statistical analysis.
• Table S7. Primer sequences for each enzyme (F: forward primer and R: reverse primer).

Download PDF